Patents by Inventor Hans-Peter Josel

Hans-Peter Josel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210102944
    Abstract: The present invention relates to a method of immobilizing a cell on a support, the method comprising a) providing a compound or salt thereof comprising, preferably consisting of, one or more hydrophobic domains attached to a hydrophilic domain, wherein the one or more hydrophobic domains are covalently bound to said hydrophilic domain, and wherein the one or more hydrophobic domains each comprise a linear lipid, a steroid or a hydrophobic vitamin, and wherein the hydrophilic domain comprises a polyethylene glycol (PEG) moiety, and wherein the compound comprises a linking group; b) contacting a cell with the compound under conditions allowing the interaction of the compound with the membrane of the cell, thereby immobilizing the linking group on the surface of the cell; and c) contacting the linking group immobilized on the cell with a support capable of binding the linking group, thereby immobilizing the cell on the support.
    Type: Application
    Filed: December 8, 2020
    Publication date: April 8, 2021
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Patent number: 10890585
    Abstract: The present invention relates to a method of immobilizing a cell on a support, the method comprising a) providing a compound or salt thereof comprising, preferably consisting of, one or more hydrophobic domains attached to a hydrophilic domain, wherein the one or more hydrophobic domains are covalently bound to said hydrophilic domain, and wherein the one or more hydrophobic domains each comprise a linear lipid, a steroid or a hydrophobic vitamin, and wherein the hydrophilic domain comprises a polyethylene glycol (PEG) moiety, and wherein the compound comprises a linking group; b) contacting a cell with the compound under conditions allowing the interaction of the compound with the membrane of the cell, thereby immobilizing the linking group on the surface of the cell; and c) contacting the linking group immobilized on the cell with a support capable of binding the linking group, thereby immobilizing the cell on the support.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: January 12, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Patent number: 10864200
    Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 15, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
  • Patent number: 10718769
    Abstract: The present invention relates to novel compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising PEG moieties, useful for binding cells, as well as uses and compositions related thereto. The compounds are useful for immobilizing and/or stabilizing cells.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 21, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Publication number: 20200024292
    Abstract: The present disclosure relates to novel multifunctionalized silicon nanoparticles, to processes for their preparation and to compositions comprising the novel multifunctionalized silicon nanoparticles. The disclosure also relates to the use of the novel multifunctionalized silicon nanoparticles in electrochemiluminescence based detection methods and in the in vitro detection of an analyte. In particular, the disclosure relates to methods for measuring an analyte by in vitro methods employing the novel multifunctionalized silicon nanoparticles.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 23, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Hans-Peter Josel, Tobias Oelschlaegel, Giuseppe Prencipe, Luisa De Cola, Elena Longhi, Chien-Wei Hsu
  • Publication number: 20200003666
    Abstract: The present disclosure relates to an in vitro method for releasing analytes from a sample involving contacting the sample with (i) a chaotropic agent, (ii) an organic solvent, (iii) a detergent, and (iv) at least one agent providing bicarbonate ions. The present disclosure further relates to a release agent for releasing analytes from a sample having the aforesaid compounds. Moreover, the present disclosure relates to uses, kits, methods and devices related to the method and the release agent of the present disclosure.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Eloisa Lopez-Calle, Ewelina Hegel, Thomas Fischer, Caroline Bylda, Hans-Peter Josel, Josef Roedl
  • Publication number: 20190388402
    Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
  • Publication number: 20190324025
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Dieter Heindl, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Florian Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Edgar Voss
  • Publication number: 20190324024
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Klaus Hirzel, Caroline Dorothea Hojer, Erasmus Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Leopold Von Proff
  • Publication number: 20190309091
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Hans-Peter Josel, Christoph Seidel, Michael Schraeml, Leopold Von Proff
  • Patent number: 10227366
    Abstract: The present invention relates to novel bis-iridium-based Ir(III) complexes, labels manufactured using these complexes and a method for producing such complexes.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 12, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Robert Cysewski, Luisa de Cola, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Gaston Hubertus Maria Vondenhoff
  • Publication number: 20180364175
    Abstract: The disclosure concerns methods for the detection of an analyte in a sample by electrochemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Hans-Peter Josel, Herbert Andres, Michaela Windfuhr, Oliver Larbolette, Stefan Quint
  • Publication number: 20180141935
    Abstract: The present invention relates to the use compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising a polyethylene glycol (PEG) moiety for stabilization of a cell, and methods related thereto.
    Type: Application
    Filed: June 20, 2016
    Publication date: May 24, 2018
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Publication number: 20170363624
    Abstract: The present invention relates to a method of immobilizing a cell on a support, the method comprising a) providing a compound or salt thereof comprising, preferably consisting of, one or more hydrophobic domains attached to a hydrophilic domain, wherein the one or more hydrophobic domains are covalently bound to said hydrophilic domain, and wherein the one or more hydrophobic domains each comprise a linear lipid, a steroid or a hydrophobic vitamin, and wherein the hydrophilic domain comprises a polyethylene glycol (PEG) moiety, and wherein the compound comprises a linking group; b) contacting a cell with the compound under conditions allowing the interaction of the compound with the membrane of the cell, thereby immobilizing the linking group on the surface of the cell; and c) contacting the linking group immobilized on the cell with a support capable of binding the linking group, thereby immobilizing the cell on the support.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 21, 2017
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Publication number: 20170269068
    Abstract: The present invention concerns an in vitro method for measurement of 25-hydroxyvitamin D, wherein the potentially interfering compound 24,25-dihydroxyvitamin D3 is blocked by a binding agent specifically binding to 24,25-dihydroxyvitamin D3 and not binding to 25-hydroxyvitamin D.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 21, 2017
    Inventors: Elke Faatz, Michael Gerg, Hans-Peter Josel, Christian Vogl
  • Publication number: 20170146533
    Abstract: The present invention relates to novel compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising PEG moieties, useful for binding cells, as well as uses and compositions related thereto. The compounds are useful for immobilizing and/or stabilizing cells.
    Type: Application
    Filed: June 20, 2016
    Publication date: May 25, 2017
    Inventors: Hans-Peter Josel, Dieter Heindl, Thomas Froehlich, Stefanie Froehner
  • Patent number: 9499573
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 22, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
  • Patent number: 9416150
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: August 16, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel
  • Patent number: 9403859
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: August 2, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel
  • Patent number: 9399654
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 26, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel